NCT00445315View on ClinicalTrials.gov

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Hepatitis C

Interventions

DRUG

PF-00868554

300 mg BID

DRUG

PF-00868554

450 mg BID

DRUG

PF-00868554

100 mg BID

DRUG

PF-00868554

300 mg TID

DRUG

Placebo

Placebo

Trial Locations (4)

1070

Pfizer Investigational Site, Brussels

10117

Pfizer Investigational Site, Berlin

12351

Pfizer Investigational Site, Berlin

DD1 9SY

Pfizer Investigational Site, Dundee

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY